Investor Relations

Latest Financial Results

Q3 2016

Quarterly Results

Ended Jun 30, 2016

Stock Information

OTCBB: AVDX Avant Diagnostics, Inc.
Day Range
52 Week Range

Company Overview

Avant is a medical diagnostic technology company that specializes in large panel biomarker tests. Our first test, OvaDx®, is proposed for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDx®. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.

Contact Information

Transfer Agent
VStock Transfer
18 Lafayette
Woodmere, NY 11598
T: (212) 828-8436

Sign up for email updates

Be the first to receive news and updates

Learn More